| Gastric cancer: epidemiology, prevention, and therapy |
39 |
| Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection |
34 |
| Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition |
25 |
| Review: Impact of Helicobacter pylori on Alzheimer's disease: What do we know so far? |
21 |
| Epidemiology of Helicobacter pylori infection |
19 |
| High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: A randomized trial |
16 |
| Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori |
15 |
| The epidemiology of Helicobacter pylori infection in Europe and the impact of lifestyle on its natural evolution toward stomach cancer after infection: A systematic review |
14 |
| Meta-analysis of three-in-one single capsule bismuth-containing quadruple therapy for the eradication of Helicobacter pylori |
14 |
| Helicobacter pylori infection reduces the risk of Barrett's esophagus: A meta-analysis and systematic review |
14 |
| Helicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of Proteobacteria and decreased relative abundances of Bacteroidetes and Actinobacteria |
13 |
| Relative potency of proton-pump inhibitors, Helicobacter pylori therapy cure rates, and meaning of double-dose PPI |
13 |
| Review: Treatment of Helicobacter pylori Infection 2019 |
12 |
| Pathogenesis of Helicobacter pylori infection |
12 |
| Helicobacter pylori infection alters gastric and tongue coating microbial communities |
11 |
| The eradication of Helicobacter pylori restores rather than disturbs the gastrointestinal microbiota in asymptomatic young adults |
11 |
| Treatment of Helicobacter pylori infection in 2018 |
11 |
| Gastric cancer: Basic aspects |
11 |
| The effect of eradication of Helicobacter pylori on gastric cancer prevention in healthy asymptomatic populations |
11 |
| Bismuth supplements as the first-line regimen for Helicobacter pylori eradication therapy: Systemic review and meta-analysis |
11 |
| Review: Epidemiology of Helicobacter pylori infection |
11 |
| Review: Diagnosis of Helicobacter pylori infection |
11 |
| Review: Helicobacter pylori and extragastric diseases |
11 |
| Seroprevalence of Helicobacter pylori in Korea: A multicenter, nationwide study conducted in 2015 and 2016 |
10 |
| Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance |
10 |
| Protocol of the European Registry on the management of Helicobacter pylori infection (Hp-EuReg) |
10 |
| Gut microbiome can be restored without adverse events after Helicobacter pylori eradication therapy in teenagers |
10 |
| Nationwide antibiotic resistance mapping of Helicobacter pylori in Korea: A prospective multicenter study |
10 |
| Review of antimicrobial peptides with anti-Helicobacter pylori activity |
10 |
| Helicobacter pylori VacA, a distinct toxin exerts diverse functionalities in numerous cells: An overview |
10 |
| Evaluation of gastric microbiome and metagenomic function in patients with intestinal metaplasia using 16S rRNA gene sequencing |
9 |
| Review: Helicobacter pylori and non-malignant upper gastrointestinal diseases |
9 |
| Review: Gastric malignancies: Basic aspects |
9 |
| Review: Gastric cancer-Clinical aspects |
9 |
| Helicobacter pylori and non-alcoholic fatty liver disease: A new enigma? |
8 |
| Effect of vitamin D on Helicobacter pylori infection and eradication: A meta-analysis |
8 |
| Molecular characterization of Helicobacter pylori resistance to rifamycins |
8 |
| Usefulness of OLGA and OLGIM system not only for intestinal type but also for diffuse type of gastric cancer, and no interaction among the gastric cancer risk factors |
8 |
| Association between Helicobacter pylori infection and nonalcoholic fatty liver disease: A systematic review and meta-analysis of observational studies |
8 |
| Helicobacter pylori and nonmalignant upper gastrointestinal diseases |
8 |
| Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial |
8 |
| Helicobacter pylori and extragastric diseases |
7 |
| Helicobacter: Inflammation, immunology, and vaccines |
7 |
| Early detection of gastric cancer after Helicobacter pylori eradication due to endoscopic surveillance |
7 |
| Real-time PCR for Helicobacter pylori diagnosis. The best tools available |
7 |
| Helicobacter Pylori infection of the gallbladder and the risk of chronic cholecystitis and cholelithiasis: A systematic review and meta-analysis |
7 |
| A meta-analysis of the association between Helicobacter pylori (H.pylori) infection and hyperemesis gravidarum |
7 |
| Systematic review and meta-analysis: Effect of Helicobacter pylori eradication on chronic spontaneous urticaria |
7 |
| Analysis of key genes and signaling pathways involved in Helicobacter pylori-associated gastric cancer based on The Cancer Genome Atlas database and RNA sequencing data |
6 |
| Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: A multicenter, prospective, randomized trial |
6 |
